Literature DB >> 20980598

Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils.

Brian O'Nuallain1, Darragh B Freir, Andrew J Nicoll, Emmanuel Risse, Neil Ferguson, Caroline E Herron, John Collinge, Dominic M Walsh.   

Abstract

Nonfibrillar, water-soluble low-molecular weight assemblies of the amyloid β-protein (Aβ) are believed to play an important role in Alzheimer's disease (AD). Aqueous extracts of human brain contain Aβ assemblies that migrate on SDS-polyacrylamide gels and elute from size exclusion as dimers (∼8 kDa) and can block long-term potentiation and impair memory consolidation in the rat. Such species are detected specifically and sensitively in extracts of Alzheimer brain suggesting that SDS-stable dimers may be the basic building blocks of AD-associated synaptotoxic assemblies. Consequently, understanding the structure and properties of Aβ dimers is of great interest. In the absence of sufficient brain-derived dimer to facilitate biophysical analysis, we generated synthetic dimers designed to mimic the natural species. For this, Aβ(1-40) containing cysteine in place of serine 26 was used to produce disulphide cross-linked dimer, (AβS26C)2. Such dimers had no detectable secondary structure, produced an analytical ultracentrifugation profile consistent for an ∼8.6 kDa protein, and had no effect on hippocampal long-term potentiation (LTP). However, (AβS26C)2 aggregated more rapidly than either AβS26C or wild-type monomers and formed parastable β-sheet rich, thioflavin T-positive, protofibril-like assemblies. Whereas wild-type Aβ aggregated to form typical amyloid fibrils, the protofibril-like structures formed by (AβS26C)2 persisted for prolonged periods and potently inhibited LTP in mouse hippocampus. These data support the idea that Aβ dimers may stabilize the formation of fibril intermediates by a process distinct from that available to Aβ monomer and that higher molecular weight prefibrillar assemblies are the proximate mediators of Aβ toxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20980598      PMCID: PMC2987723          DOI: 10.1523/JNEUROSCI.3537-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  47 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

3.  Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems.

Authors:  Peter Schuck; Matthew A Perugini; Noreen R Gonzales; Geoffrey J Howlett; Dieter Schubert
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

4.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels.

Authors:  A Shevchenko; M Wilm; O Vorm; M Mann
Journal:  Anal Chem       Date:  1996-03-01       Impact factor: 6.986

Review 5.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

Authors:  J D Harper; P T Lansbury
Journal:  Annu Rev Biochem       Date:  1997       Impact factor: 23.643

6.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Authors:  L F Lue; Y M Kuo; A E Roher; L Brachova; Y Shen; L Sue; T Beach; J H Kurth; R E Rydel; J Rogers
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation.

Authors:  Dean M Hartley; Chaohui Zhao; Austin C Speier; Gavitt A Woodard; Shaomin Li; Zongli Li; Thomas Walz
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

9.  Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity.

Authors:  Lin Wai Hung; Giuseppe D Ciccotosto; Eleni Giannakis; Deborah J Tew; Keyla Perez; Colin L Masters; Roberto Cappai; John D Wade; Kevin J Barnham
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

10.  Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice.

Authors:  Ivo Cristiano Martins; Inna Kuperstein; Hannah Wilkinson; Elke Maes; Mieke Vanbrabant; Wim Jonckheere; Patrick Van Gelder; Dieter Hartmann; Rudi D'Hooge; Bart De Strooper; Joost Schymkowitz; Frederic Rousseau
Journal:  EMBO J       Date:  2007-12-06       Impact factor: 11.598

View more
  108 in total

1.  Probing amyloid fibril growth by two-dimensional near-ultraviolet spectroscopy.

Authors:  Jun Jiang; Shaul Mukamel
Journal:  J Phys Chem B       Date:  2011-04-25       Impact factor: 2.991

Review 2.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

3.  What Can the Kinetics of Amyloid Fibril Formation Tell about Off-pathway Aggregation?

Authors:  Rosa Crespo; Eva Villar-Alvarez; Pablo Taboada; Fernando A Rocha; Ana M Damas; Pedro M Martins
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

Review 4.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

5.  Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.

Authors:  Ming Jin; Nina Shepardson; Ting Yang; Gang Chen; Dominic Walsh; Dennis J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-18       Impact factor: 11.205

Review 6.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes.

Authors:  Iryna Benilova; Eric Karran; Bart De Strooper
Journal:  Nat Neurosci       Date:  2012-01-29       Impact factor: 24.884

7.  Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease.

Authors:  Marc Aurel Busche; Xiaowei Chen; Horst A Henning; Julia Reichwald; Matthias Staufenbiel; Bert Sakmann; Arthur Konnerth
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-16       Impact factor: 11.205

8.  A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.

Authors:  Yona Levites; Brian O'Nuallain; Rama Devudu Puligedda; Tomas Ondrejcak; Sharad P Adekar; Cindy Chen; Pedro E Cruz; Awilda M Rosario; Sallie Macy; Alexandra J Mably; Dominic M Walsh; Ruben Vidal; Alan Solomon; Daniel Brown; Michael J Rowan; Todd E Golde; Scott K Dessain
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

9.  The Aggregation Paths and Products of Aβ42 Dimers Are Distinct from Those of the Aβ42 Monomer.

Authors:  Tiernan T O'Malley; William M Witbold; Sara Linse; Dominic M Walsh
Journal:  Biochemistry       Date:  2016-10-26       Impact factor: 3.162

10.  Amyloid-β(1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia.

Authors:  Geeta S Paranjape; Shana E Terrill; Lisa K Gouwens; Benjamin M Ruck; Michael R Nichols
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.